Home / Companies / Esperion Therapeutics, Inc. / 29 May 2025
Esperion Therapeutics, Inc.: meeting of 29 May 2025
Votes reported on Form N-PX, item by item
190 Form N-PX filers reported votes at the Esperion Therapeutics, Inc. meeting of 29 May 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 88.5% of reported votes for; 17 filers withheld from or voted against at least one nominee.
208 vote records from 53 filers. 1 of the 53 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
259 vote records from 188 filers. 35 of the 180 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
104 vote records from 53 filers. 0 of the 53 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
106 vote records from 55 filers. 1 of the 55 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| State Street and SPDR | For | For | For |
| Invesco | Split or no vote | For | For |
| Equitable | For | For | For |
| Charles Schwab | Split or no vote | For | For |
| Nuveen and TIAA | Split or no vote | For | For |
| ProShares and ProFunds | For | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | No report | Against * | No report |
| Northern Trust and FlexShares | Split or no vote | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | Split or no vote | For | For |
| Voya | Split or no vote | For | For |
| Nationwide | For | Against * | For |
| Victory Capital | For | For | For |
| Brighthouse Funds | For | For | For |
| Guggenheim and Rydex | For | For | For |
| Columbia Threadneedle | Split or no vote | For | For |
| BNY Mellon | No report | For | No report |
| Principal | No report | For | No report |
| Pacific Life funds | For | For | For |
| Global X | For | Against * | For |
| AllianceBernstein | No report | For | No report |
| DWS | For | For | For |
| Allspring | No report | For | No report |
| MassMutual | No report | For | No report |
| Neuberger Berman | No report | Against * | No report |
| Baird | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Esperion Therapeutics, Inc. meeting?
190 Form N-PX filers reported votes at the meeting of 29 May 2025. On say-on-pay, 35 of 180 voted against management (19.4%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Esperion Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Esperion Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Esperion Therapeutics, Inc. with a meeting date within three days of 29 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.